Loading...
XNAS
LNSR
Market cap133mUSD
Dec 05, Last price  
11.20USD
1D
-1.67%
1Q
-7.97%
IPO
-8.20%
Name

LENSAR Inc

Chart & Performance

D1W1MN
XNAS:LNSR chart
P/E
P/S
2.50
EPS
Div Yield, %
Shrs. gr., 5y
1.60%
Rev. gr., 5y
11.87%
Revenues
53m
+26.87%
24,388,00030,528,00026,382,00034,459,00035,358,00042,164,00053,494,000
Net income
-31m
L+118.34%
-12,593,000-16,716,000-21,182,000-19,652,000-19,651,000-14,383,000-31,404,000
CFO
-2m
L-76.45%
-1,885,000-12,589,000-13,791,000-8,969,000-14,856,000-9,659,000-2,275,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. Its LENSAR Laser System incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, procedure planning, design, and precision. The company was incorporated in 2004 and is headquartered in Orlando, Florida.
IPO date
Sep 21, 2020
Employees
110
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT